About Medlab
Medlab is a publicly listed company based in Sydney (Australia) founded in 2012 by Sean Hall. Pharmaceuticals, nutraceuticals, and biologics are developed for chronic disease treatment. Its chief executive, as recorded, is Sean Hall. Its focus areas include Life Sciences, Nutraceuticals Tech, Dietary Supplements and Disease Specific.
Company details
Founded in 2012 and based in Sydney, Australia, Medlab is involved in the research and development of bio-based therapeutics targeting early to moderate chronic diseases, including chronic kidney disease and prediabetes or obesity. Operations center on biologics that address pathophysiological processes, with evaluation of gastrointestinal microbiome perturbations and probiotic bacterias potential to influence health outcomes. Lead programs focus on cardiometabolic conditions, central nervous system disorders, and aging.
- Investors
Funding Insights of Medlab
- Total Rounds 3
- First Round $19.31M
(Jan 2018)
- Investors Count 1
All 3 funding rounds of Medlab with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | Grant | – | – | ||
| Dec 2019 | $3.44M | Post-IPO | – | – | – |
| Jan 2018 | $19.31M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Medlab
Medlab has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include NSW.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Wealth fund management is overseen by the NSW government entity. | 1856 | nsw.gov.au | Sydney, Australia |
Investor details for Medlab
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Medlab
1 people are tracked at Medlab (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sean Hall | Founder & CEO | Leadership |
Complete people profiles for Medlab
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Medlab
4 dated milestones of Medlab across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Medlab is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $19.3M.
- Funding Latest funding round, Grant,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medlab
Complete news archive for Medlab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medlab
Medlab was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Medlab is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Sean Hall is the CEO of Medlab, as recorded in our data. They have also founded this company.
Founded in 2012 and based in Sydney, Australia, Medlab is involved in the research and development of bio-based therapeutics targeting early to moderate chronic diseases, including chronic kidney disease and prediabetes or obesity. Operations center on biologics that address pathophysiological processes, with evaluation of gastrointestinal microbiome perturbations and probiotic bacterias potential to influence health outcomes. Lead programs focus on cardiometabolic conditions, central nervous system disorders, and aging.
Medlab has 1 investor. Key investors include NSW.